Clinical Trial Update: Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Everolimus to placebo in patients with advanced pancreatic neuroendocrine tumors reports efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Neuroendocrine Tumors of Pancreatic Origin | Phase 3 | Status: COMPLETED | Results posted: 2011-12-15